Key result
Aggressive combined modality therapy for advanced local-regional breast carcinoma resulted in a 65% actuarial three-year survival and a median disease-free survival of 29.5 months.
Why the study?
Does aggressive combined modality therapy improve survival in women with advanced local-regional breast carcinoma?
Cohort (n=32)
Does aggressive combined modality therapy improve survival in women with advanced local-regional breast carcinoma?
Aggressive combined modality therapy for advanced local-regional breast cancer yields a 65% three-year survival rate but is associated with significant cardiotoxicity, particularly when involving left chest irradiation and doxorubicin.
Answers are grounded in this paper and cite their sources.
Should not change practice given cardiotoxicity risks; hypothesis-generating for combined modality therapy in advanced breast cancer.
Thirty-two women with advanced local regional breast carcinoma, including nine patients with histologically diagnosed inflammatory cancer, were entered on a prospective pilot study. They were treated aggressively with initial surgery, two courses of induction chemotherapy with cyclophosphamide, methotrexate, 5-fluorouracil, +/- prednisone, +/- tamoxifen (CMF [P] [T]), local-regional radiotherapy, and then maintenance chemotherapy with CMF(P) (T) alternating with doxorubicin, vincristine, +/- tamoxifen (AV[T]). The patients have been followed for 19-70 months from the time of mastectomy and their actuarial three-year survival is 65% with a median survival that has not yet been reached. Median disease-free survival (time to progression) is currently 29.5 months. Women whose gross disease could not be totally resected surgically had shorter disease-free survivals than those rendered surgically free of disease (p = 0.01). Clinically evident cardiotoxicity was seen in 25% of the patients and was felt to be primarily due to the combination of doxorubicin and radiation therapy. It was significantly more common (Plt less than 0.05) in patients with left chest irradiation (seven of 18 women) as opposed to those with right-sided irradiation (one of 14).
No takes yet. Share an insight, caveat, or question.
Loprinzi et al. (1984) conducted a cohort in advanced local-regional breast carcinoma (n=32). Aggressive combined modality therapy (surgery, induction CMF[P][T], radiotherapy, and maintenance CMF[P][T] alternating with AV[T]) was evaluated on Actuarial three-year survival. Aggressive combined modality therapy for advanced local-regional breast carcinoma resulted in a 65% actuarial three-year survival and a median disease-free survival of 29.5 months.
Synapse has enriched 10 related papers. Consider them for comparative context: